Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor.
about
Dendritic cell generation and CD4+ CD25high FOXP3+ regulatory t cells in human head and neck carcinoma during radio-chemotherapy.Dendritic Cells (DC) Facilitate Detachment of Squamous Carcinoma Cells (SCC), While SCC Promote an Immature CD16(+) DC Phenotype and Control DC Migration.Progress and challenges in the vaccine-based treatment of head and neck cancers.Head and neck tumour immunology: basic concepts and new clinical implications.Development of multi-epitope vaccines targeting wild-type sequence p53 peptides.Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck.Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functionsThe current state of head and neck cancer gene therapy.Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen.The clinical implications of antitumor immunity in head and neck cancer.Immune alterations and immunotherapy prospects in head and neck cancer.Lentiviral vector-based therapy in head and neck cancer (Review)Immunotherapy with dendritic cells in an animal model of early pulmonary metastatic squamous cell carcinoma.Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma.Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients.Emerging drugs for head and neck cancer.Intense Foxp3+ CD25+ regulatory T-cell infiltration is associated with high-grade cutaneous squamous cell carcinoma and counterbalanced by CD8+/Foxp3+ CD25+ ratio.
P2860
Q35963926-2918F134-346E-4684-BDC2-D20058E2A3A7Q36695094-52AE66D4-0E74-4EAC-AB8C-560638CD3E91Q37224926-6E3D22D6-7CB2-40E7-AD13-1AB600FAF8DEQ37257773-DA373865-1CCE-4FAF-B449-74F305E514D4Q37259621-4782802E-5D1A-4836-894F-819B36EFC5CFQ37334966-146FEC93-91D7-4552-BBD8-1AD9333DB870Q37352465-DDA86377-507F-43CC-B1F0-A3AF9FC6D804Q37595513-F7E75E5C-2C6E-46FC-912D-F7DC463C5E92Q37634052-2FD495F2-FD47-4D1A-9160-5C4153B3D7DFQ37970005-D631D594-D45C-4DBB-A91D-383202D2AF90Q38116067-434C0719-5644-4769-8F2A-8093A2BF9A83Q38172153-5CC0BAFC-D99E-4928-A7D8-276F1BCFC682Q38459009-38F58038-4B4D-446A-9A7D-C9AFABDF8CBEQ41237376-D891996B-1459-4E5B-BB08-7D57FCC085C9Q41503180-76D37926-2D02-424F-B4ED-D9EBFC3FAF84Q45874449-CEDCBAF0-221B-46DA-8041-258912570920Q46523472-43C57F8F-9376-4BAD-985E-8CC51A08B83F
P2860
Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor.
@en
Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor.
@nl
type
label
Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor.
@en
Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor.
@nl
prefLabel
Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor.
@en
Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor.
@nl
P1476
Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor.
@en
P2093
Theresa L Whiteside
P304
P356
10.2174/156800907782418310
P577
2007-11-01T00:00:00Z